Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$4.55
-0.9%
$5.13
$3.51
$17.40
$39.31M0.3382,104 shs99,040 shs
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$17.01
-3.4%
$18.32
$14.06
$27.29
$1.87B0.01639,792 shs807,213 shs
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$1.54
$1.55
$0.60
$4.69
$128.53M1.271.47 million shsN/A
XOMA Co. stock logo
XOMA
XOMA
$24.92
+0.3%
$22.67
$18.35
$35.00
$298.22M0.8930,822 shs21,233 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-0.87%-11.82%-19.04%-53.71%-71.11%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-3.41%-12.09%-2.91%-13.70%-9.62%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
XOMA Co. stock logo
XOMA
XOMA
+0.28%-6.32%+3.23%+8.68%+0.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.9502 of 5 stars
3.50.00.04.63.62.50.6
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
2.5779 of 5 stars
3.51.00.00.02.85.00.0
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
4.0922 of 5 stars
3.52.00.03.03.23.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.00
Buy$43.20849.45% Upside
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
3.00
Buy$43.00152.79% Upside
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00
N/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
3.00
Buy$69.50178.89% Upside

Current Analyst Ratings Breakdown

Latest KPTI, NGM, NAMS, and XOMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00
5/13/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.00
5/8/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $40.00
4/17/2025
XOMA Co. stock logo
XOMA
XOMA
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
4/8/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
3/28/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
3/19/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
3/3/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$41.00
3/3/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$75.00 ➝ $54.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$142.13M0.28N/AN/A($1.47) per share-3.10
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$47.14M39.63N/AN/A$3.50 per share4.86
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$4.42M29.10N/AN/A$1.80 per share0.86
XOMA Co. stock logo
XOMA
XOMA
$13.05M22.86N/AN/A$7.72 per share3.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$143.10M-$13.26N/AN/AN/A-52.62%N/A-39.58%8/5/2025 (Estimated)
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/A
XOMA Co. stock logo
XOMA
XOMA
-$40.83M-$1.15N/AN/AN/A-151.34%-24.95%-9.64%8/12/2025 (Estimated)

Latest KPTI, NGM, NAMS, and XOMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
XOMA Co. stock logo
XOMA
XOMA
-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million
5/12/2025Q1 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million
5/8/2025Q1 2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million
3/17/2025Q4 2024
XOMA Co. stock logo
XOMA
XOMA
-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
1.70
2.93
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/A
10.61
10.61
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/A
7.79
7.79
XOMA Co. stock logo
XOMA
XOMA
1.28
7.52
7.52

Institutional Ownership

CompanyInstitutional Ownership
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
89.89%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
75.74%
XOMA Co. stock logo
XOMA
XOMA
95.92%

Insider Ownership

CompanyInsider Ownership
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.75%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
20.84%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
35.90%
XOMA Co. stock logo
XOMA
XOMA
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3808.64 million122.72 millionOptionable
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
4109.82 million74.37 millionOptionable
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
13883.46 million53.50 millionOptionable
XOMA Co. stock logo
XOMA
XOMA
1011.97 million10.94 millionOptionable

Recent News About These Companies

XOMA Royalty Reports Strong Q1 2025 Results
XOMA Royalty: Q1 Earnings Snapshot
High Growth Tech Stocks In The US To Watch April 2025
Xoma initiated with a Buy at Benchmark

New MarketBeat Followers Over Time

Media Sentiment Over Time

Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$4.55 -0.04 (-0.87%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.59 +0.04 (+0.88%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$17.01 -0.60 (-3.41%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$17.01 0.00 (0.00%)
As of 05/27/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NGM Biopharmaceuticals stock logo

NGM Biopharmaceuticals NASDAQ:NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

XOMA stock logo

XOMA NASDAQ:XOMA

$24.92 +0.07 (+0.28%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$24.95 +0.03 (+0.12%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.